Background: This article is presented to provoke further discussion regarding the use of thrombolj drugs to treat acute ischemic stroke.
S troke has defied the considerable efforts of medical science to find an effective treatment and remains the third most common cause of death in the developed world, preceded only by ischemic heart disease and all cancers combined. 1 However, unlike ischemic heart disease and cancer, stroke leaves many more people disabled and dependent on family and social or health services. Despite a decline in stroke mortality in some but not all countries, 1 there is rather little evidence of a decline in incidence. 2 Therefore, anticipated demographic changes, and thus increasing stroke numbers, make it even more important to find an effective treatment. 3 Therapeutic approaches should reflect logical application of our present understanding of the sequence of events in the ischemic brain leading to cerebral infarction. After interruption of the blood supply, some tissue probably suffers irreperable damage within minutes, but a variable amount remains in a "shut-down" but viable state for several hours. 4 The concept of this "ischemic penumbra" is now reasonably well established by electrophysiological work in animals 4 and positron emission tomography. 5 Neutralization of toxic metabolites released from infarcted cells or restoration of the blood supply might save the ischemic tissue and improve outcome. Thus two basic approaches have evolved: 1) to protect ischemic but still viable neurons from further damage by toxic metabolites and 2) to improve the blood supply to ischemic brain.
Using the first approach, nimodipine has not been shown to be of any benefit in moderately large groups of patients. 6 Newer excitatory amino acid antagonists are being evaluated but may have unacceptable toxicity (e.g., psychosis and cardiac arrhythmias), and it remains to be seen whether the benefit in animals can be translated into benefit in elderly stroke patients. 7 Using the second approach, hemodilution is ineffective in the generality of ischemic stroke patients. 8 Antithrombotic therapy (with heparin, warfarin, or aspirin) has not been properly tested in large randomized clinical trials. Although variably used in acute stroke, 9 we do not know if these drugs improve outcome. A randomized trial of aspirin and heparin in acute ischemic stroke has begun in Europe.
That leaves thrombolysis, a theoretically attractive treatment with proven ability to dissolve arterial thrombus elsewhere in the body 10 but with the potentially unattractive adverse effect of converting a simple (pale) infarct into a hematoma. Thrombolytic drugs were first used in the late 1950s for acute stroke. 11 Since then over 2,800 patients have been reported in the world literature. Despite this we do not know if thrombolysis works, nor what the risks of treatment are. Most of the literature consists of case reports or small series, with only six small randomized trials. 12 - 17 Rather than review historically the use of thrombolytic drugs to treat cerebral ischemia, 18 it is our intention to examine critically and quantitatively the evidence that thrombolytic drugs might work in acute ischemic stroke without unacceptable risks.
Wardlaw and WaHow Thrombolysis in Acute Ischemic Stroke
Given the heterogeneity of the pathogenesis and outcome of acute ischemic stroke and that the magnitude of any treatment effect may be modest, both a proper control group and adequate numbers of patients are essential to ensure an unbiased and precise trial result. 19 Many of the reported studies have methodological inadequacies that make their evaluation of thrombolysis in acute stroke inconclusive. We hope to demonstrate in this article that thrombolysis has a good chance of improving outcome in acute ischemic stroke without unacceptable risk, and that properly conducted large randomized trials (on the scale of the myocardial infarction thrombolysis trials) would be reasonable to do and likely to yield a definitive answer; indeed, several less ambitious trials have already started (see below).
Why Might Thrombolysis Work?
The majority of acute focal cerebral ischemic events are due to embolism or in situ thrombosis. 20 A small proportion are due to "boundary zone" ischemia secondary to a hypotensive episode or internal carotid artery (ICA) occlusion. Approximately 20% are small subcortical infarcts commonly attributed to degenerative changes in small perforating arteries, 21 although some authors dispute this. Most of the discussion in this article will refer to large artery territory thromboembolic stroke.
Thrombolytic drugs work in acute myocardial infarction, which is usually due to acute thrombotic occlusion of a coronary artery, by lysing the thrombus quickly and restoring vessel patency. 22 The Second International Study of Infarct Survival (ISIS-2) showed that streptokinase (SK) reduced mortality after myocardial infarction by 25%.
a Aspirin confers similar benefit, and the effect of both is a 50% reduction in mortality at 5 weeks. The cause of many acute ischemic strokes, as outlined above, is acute embolic or thrombotic cerebral artery occlusion. Therefore, there are good theoretical reasons why thrombolysis might also work in the cerebral circulation.
In the brain, the information on spontaneous recanalization of thrombotic or embolic cerebral artery occlusion is scanty. Based on the limited evidence available from Caucasian populations, about 20% of presumed embolic (cardiac or artery-to-artery) middle cerebral artery (MCA) occlusions (main stem or branch) may recanalize spontaneously within 24 hours, and possibly as many as 80% do so within 1 week of onset, 24 -25 but these figures are no more than "best estimates." It is difficult to extract the spontaneous lysis rate of artery-to-artery embolism from the figures for cardiac embolism (often patients have both potential sources), and there is little information on recanalization of acute ICA occlusions in the neck. Spontaneous reperfusion after thrombotic cerebral artery occlusion (thought to be more common in Oriental peoples) has been little studied but appears to be less likely than recanalization after embolic occlusion. 2627 Therefore, in the population with ischemic stroke due to large vessel disease, the spontaneous recanalization rate will be at best approximately 20% at 24 hours but may depend on the location of the occlusion (ICA or MCA), its composition (fibrin embolus, platelet embolus, or thrombus), and its age. Although these figures emphasize the lack of information regarding spontaneous recanalization of occluded cerebral arteries, there is clear evidence that spontaneous lysis of thrombus does occur. So the question for thrombolytic therapy is whether this spontaneous process can be accelerated in time to restore useful brain function without unacceptable risk.
What Do We Know So Far From Using Thrombolytic Drugs in Ischemic Stroke?
There have been over 60 reports in the world literature to date. Six were randomized trials, 12 " 17 and four had retrospective or nonrandom control groups. 28 " 31 Of the remaining, 35 or more were so-called open trials and approximately 20 were case reports. The trials were identified by literature search (using Index Medicus), by tracing references cited in thrombolysis articles, and by discussion with other researchers interested in thrombolysis. All published randomized trials are included in this analysis as well as all nonrandomized trials and most case reports in the English, French, German, and Japanese literature. It is probable that some acute stroke patients have been treated with thrombolysis but not reported in the literature, and potential bias because of this must be borne in mind when interpreting the following analysis.
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Randomized Trials
Of the six randomized trials shown in Table 1 and Figure 1 , the two by Meyer et al 12 - 13 were conducted before the invention of computed tomographic (CT) scanning, and therefore some patients with primary intracerebral hemorrhage or hemorrhagic infarction may inadvertently have been included. The numbers were small, and the outcome measure was clinical evaluation at 10 days, which may be too early for valid assessment. In the first study there was no difference in outcome between the treated and control groups. In the second, larger study, the treated group fared worse. However, patients were included up to 72 hours after onset, and although the mean time to treatment was not stated, trial intervention may have been too late. It is generally thought that treatment for acute ischemic stroke should begin as soon as possible, certainly within 24 hours of onset.
The randomized trials by Mori et al, 14 Ohtomo et al, 15 Abe et al, 16 and the Japanese Thrombolysis Study Group (JTSG) 17 used CT scanning to exclude intracerebral hemorrhage as a cause of stroke before randomization and for follow-up after treatment. Mori et al studied MCA and ICA recanalization and found that nine of 19 patients given intravenous tissue plasminogen activator (t-PA) within 6 hours of symptom onset recanalized compared with three of 12 given placebo. Ohtomo et al published a Japanese multicenter randomized trial of low-dose intravenous urokinase (UK) in acute thrombotic cerebral infarction given within 5 days of symptom onset. Abe et al (also Japanese) published a randomized trial of intravenous urokinase for acute ischemic stroke given up to 30 days after symptom onset (more than half of the patients were treated 4 days or more after onset). The JTSG 17 studied clinical improvement after embolic stroke and found that 37 of 51 patients randomized to 34 mg t-PA i.v. improved compared with 26 of 47 given placebo within 6 hours of symptom onset. Additional information on drug, dosage, route of administration, time to treatment, and outcome measure is given in Table 1 . Note No., total number of patients in each group; %, % of patients who improved clinically, or recanalized. 14 Where two assessment times are given, the % improved refers to the later time. JTSG, Japanese Thrombolysis Study Group; Fib, fibrinoh/sin; Pla, plasmin; SK, streptokinase; t-PA, tissue-type plasminogen activator; UK, urokinasc; IV, intravenous; IA, intra-arterial.
that Table 1 includes not only the six truly randomized trials (upper half) but also the four nonrandomized trials (described below), which are often referred to as "controlled" trials in the literature to emphasize the distinction. Figure 1 shows the results of an overview analysis 33 of death ( Figure IA ) and death or deterioration ( Figure  IB ) after thrombolytic therapy for acute ischemic stroke. The analysis is of published results for the six randomized trials, and additional information was supplied by E. Mori and T. Yamaguchi for the JTSG. Although deterioration was assessed differently in each trial, the overview technique minimizes the problem of trying to compare different trials and end point measures by not comparing randomized, controlled trials directly with each other. Rather, the overview compares the magnitude and direction of any treatment effect contained within the individual trials and yields an estimate of the overall treatment effect.
Analysis of all six trials shows that the risk of death is increased by 20% with thrombolysis but with a wide confidence interval (CI) that includes the possibility of a 31% reduction to 151% excess. The risk of death or deterioration (all six trials) is reduced by 37% with thrombolysis, but the wide CI includes the possibility of a 66% reduction to 14% excess.
Analysis of the four trials conducted with the benefit of CT scanning (therefore reliably excluding cerebral hemorrhage as the cause of symptoms) shows a reduction in the risk of death of 37% (95% CI, 74% reduction to 47% excess) with thrombolytic treatment and shows a reduction in the risk of death or deterioration of 56% (95% CI, 20-76% reduction [2/>=0.007]). This provides some evidence that thrombolysis is beneficial in acute ischemic stroke; this benefit is not enough to recommend routine treatment but certainly enough to encourage larger randomized trials.
Studies With a Retrospective or
Nonrandom Control Group The study by Hacke et al 28 on vertebrobasilar occlusion illustrates the difficulty of including a retrospective control group (Table 1) . Although the treated and control groups were similar in many respects, 12 of 22 (54%) of the control subjects were unconscious at diagnosis and entry into the trial compared with 15 of 43 (35%) of the treated group, perhaps reflecting increasing awareness of the condition and earlier diagnosis. Epidemiological studies have shown that vertebrobasilar stroke can cause mild symptoms and does not always progress to coma with the uniformly bleak outcome that Hacke et al have suggested. 34 Therefore, the prospective treated and retrospective control patients may have been different in prognosis, and it is not valid to use the sicker group treated conventionally as a control for the later treated group. The other three studies that in- Open Trials and Case Reports The primary aim of the studies shown in Tables 2 and  3 was to assess safety and find an optimal dose. They are a heterogeneous group of reports, some using the intravenous and some the intra-arterial route of drug administration, with different drugs, doses of drug, inclusion criteria, and outcome events (recanalization or clinical improvement). It is not possible to make any comment about benefit because there were no control groups. It is even difficult to draw any conclusions about safety because the natural history of cerebral infarction is so variable and there were no control subjects with which the development of cerebral edema or hemorrhagic transformation could be compared.
The studies that examined reperfusion (using serial angiography) considered together showed some degree of recanalization (partial or complete) in 61% of patients within 24 hours of symptom onset. This appears to be better than the estimated spontaneous rate of recanalization of 20% at 24 hours after onset (see above). It is encouraging that 61% recanalization is of the same order of magnitude as was found in the acute myocardial infarction thrombolysis studies, which used angiography to assess recanalization. 70 Although these figures are very tentative, all available data are included and suggest the presence of a useful treatment effect.
These conclusions are encouraging but tentative, the numbers of patients are small, and there may have been publication bias, 32 although in the field of thrombolysis in acute ischemic stroke positive as well as negative results seem to be presented with equal enthusiasm. Does Thrombolysis Increase the Risk of Cerebral Hemorrhage? Thrombolytic drugs given for extracranial vascular disease increase the risk of hemorrhage both in the brain and elsewhere in the body. 23 Therefore, thrombolysis for acute ischemic stroke might increase the risk of cerebral hemorrhage, but how big is this risk? Thrombolysis might, by reducing infarct size or other mecha- nism, actually reduce the rate of hemorrhagic transformation of the cerebral infarct. 71 There is relatively little good information on the "natural" rate of hemorrhagic transformation of acute ischemic strokes. Most reported studies are limited by the method of patient selection, for example, postmortem series, retrospective CT studies, and some prospective CT studies in which only patients who deteriorated were scanned. In addition, most studies include some patients who received antithrombotic treatment of some sort, and thus for several reasons these studies may have overestimated the frequency of hemorrhagic transformation. There is only one prospective study that used serial CT scanning at predetermined intervals after acute ischemic stroke (regardless of symptoms), and it suggested that approximately 5% of simple (pale) infarcts undergo symptomatic hemorrhagic transformation with formation of space-occupying hematomas 72 (some patients in that study also received antithrombotic treatment). Pathological studies show some degree of petechial hemorrhage in almost all infarcts, although CT scanning detects this less frequently. 7173 Petechial hemorrhage is thought to be asymptomatic and thus probably is not clinically important, although this has not been studied. Based on the best information available, we estimate that the spontaneous rate of symptomatic hemorrhagic transformation of the infarct is approximately 5% 72 and that the rate of asymptomatic (petechial) hemorrhagic transformation is between 15% and 45%, 73 but this may be an overestimate. The rate probably varies with the extent of the infarct 71 and possibly with stroke etiology. 73 Using all the published data available, we have estimated the rate of hemorrhagic transformation after thrombolysis for acute ischemic stroke (Tables 4 and 5 ). The true rate of hemorrhagic transformation can only be found from large randomized, controlled trials (including at least several thousand patients), but summing all the data available at present may at least give an estimate of the likely order of magnitude of hemor- Studies are listed according to drug used and increasing dose. Various different measures were used to determine clinical improvement, and patients with various types of acute ischemic stroke syndrome were included. NIH, National Institutes of Health; No. of patients, total number of patients in study, SK, streptokinase; UK, urokinase; t-PA, tissue-type plasminogen activator; IA, intra-arterial; TV, intravenous.
rhagic transformation. All the data, including case reports, have been included to give as unbiased an assessment as can be obtained at present. Note that the time to treatment, duration of treatment, route of administration, type of drug, and total dose of thromborytic drug (in some studies very low doses of thrombolytic drug were used), definition of symptomatic and asymptomatic hemorrhagic transformation, and patient characteristics were different in each study. Therefore, this analysis can only provide an estimate of the likely hemorrhagic transformation rate. Table 4 shows the rate of asymptomatic petechial hemorrhagic transformation (without clinical deterioration), and Table 5 shows the rate of symptomatic intracerebral hematoma formation (with clinical deterioration) after thrombolysis. Note the huge variation in the reported rate of asymptomatic petechial hemorrhage. This may partly reflect bias in interpretation of CT scans, or it may be Cerebral hematomas were diagnosed by routine computed tomographic brain scan or post mortem. Studies are listed according to drug used and increasing dose. No. of patients, total number of patients in study; ASSG, Acute Stroke Study Group; JTSG, Japanese Thrombolysis Study Group; NTH, National Institutes of Health; F, fibrinolysin; T, thrombolysin; SK, streptokinase; UK, urokinase; t-PA, tissue-type plasminogen activator, IV, intravenous; IA, intra-arterial. due to different frequencies and timing of C T scanning after thrombolysis, different doses of drug, or inclusion of different types of ischemic stroke and thus should be viewed with this in mind. The estimated rate of symptomatic intracerebral hematoma formation after thrombolysis (5%) is similar to the estimated expected natural history. The cerebral hematoma rate varies between studies and appears to be higher with t-PA (Figure 2 ). Although this may be due to a number of factors including differences in frequency and timing of CT scanning, postmortem rates, or different doses of drug, the trend is similar to the cerebral hemorrhage rate found when SK and t-PA were compared in ISIS-3 87 and GISSI-2 88 in acute myocardial infarction. Ascertainment of the true cerebral hemorrhage rate with each thrombolytic drug will only be possible by direct comparison in large randomized trials similar to the myocardial infarction studies. 87 - 88 Two small randomized trials that compared low-dose UK with t-PA 54 -59 found no significant difference in outcome or hemorrhagic transformation rates.
The randomized trials (with CT scanning) all found massive hemorrhagic infarction slightly more often in placebo-treated than in thrombolysis-treated patients. Mori et al 14 found hemorrhagic transformation of mild degree in 26% of t-PA-treated and 33% of placebotreated patients. Ohtomo et al 15 found that two of 169 UK-treated patients developed hemorrhagic transformation of the infarct of mild degree, whereas one of 181 placebo-treated patients developed a severe symptomatic intracerebral hematoma. Abe et al 16 found no symptomatic intracerebral hematomas with UK. In the JTSG trial there were massive hemorrhagic infarcts in four of 51 patients in the t-PA-treated group and in five of 47 patients in the control group. 17 None of the large open stroke trials found a relation between dose of drug and symptomatic intracerebral hematoma formation, but they suggested that a time delay of over 6 hours from onset, 52 hypertension, and possibly treating patients who already had a low-density area visible on CT may be risk factors.
55i68a ' 68b Matsumoto and Satoh 49 have treated 52 acute ischemic stroke patients with a wide range of doses of UK and have not demonstrated any definite relation between cerebral hemorrhage and dose, time after onset, or age of patient. They suggested that hemorrhages were more often symptomatic in recanalized patients, but this conclusion was based on very small numbers (Figure 3) . No definite association with recanalization was found in the Acute Stroke Study Group trial 52 or by Miyakawa and Sakuragawa. 50 Therefore, it appears that although one might expect thrombolytic treatment to increase symptomatic hemorrhagic transformation of cerebral infarcts, using the limited data available at present, the risk is of an order of magnitude similar to the estimated natural rate. The true risk of hemorrhagic transformation of the cerebral infarct after thrombolysis can be found only by large randomized, controlled trials using serial CT scanning (or magnetic resonance imaging or postmortem series when appropriate) in all patients.
Does Thrombolysis Increase the Risk of
Space-Occupying Edema Formation in the Cerebral Infarct? The cause of severe infarct edema is unclear. It may be due to "reperfusion injury," and therefore thrombolysis might worsen this condition. 89 As far as can be ascertained, severe infarct edema is not simply due to recanalization 9091 and occurs naturally in approximately 5% of large infarcts. 71 However, the data on symptomatic cerebral infarct edema formation are even more limited than those for hemorrhagic transformation (Table 6). The frequency of cerebral edema with brain herniation is difficult to extract from the thrombolysis studies but does not appear to be increased. Many studies did not mention severe infarct swelling, although it may have occurred. Mori et al 14 found that massive brain swelling occurred in 9% of patients who reperfused compared with 35% who did not (26% of t-PAtreated and 25% of placebo-treated patients).
We have prospectively examined reperfusion in 47 patients with partial or total MCA territory infarcts 92 : infarct swelling was greatest in the largest infarcts and in patients whose symptomatic MCA remained occluded on angiography or transcranial Doppler ultrasound. Patients who reperfused within the first 3 days of onset had smaller infarcts with less edema and a better clinical outcome.
What About Dose and Mode of Administration of Thrombolysis, Elderly Patients, and Time Limit
to Treatment After Onset? To avoid delay, any treatment for acute stroke must be easy to administer. The standard intravenous dose for myocardial infarction is 1.5 megaunits SK or 100 mg t-PA. Smaller intracoronary doses were used in early studies to try to maximize local thrombolytic effect and reduce systemic adverse effects, but any benefit was more than offset by the extra 1 or 2 hours of delay caused by angiography. 93 Intravenous administration of thrombolysis would also be quicker than intra-arterial administration in acute ischemic stroke.
If thrombolysis is to be a worthwhile treatment for acute ischemic stroke, it should be available for the elderly, the most commonly affected age group. Cerebral amyloid angiopathy has been cited as a reason for increased risk of hemorrhage in the elderly. 94 The few studies in which thrombolytics have been used in elderly stroke patients (aged older than 70 years) do not show a definitely increased hemorrhage rate compared with younger patients. Figure 3 shows the results of Matsumoto and Satoh 49 in patients aged up to 86 years. The 23 showed that in elderly myocardial infarct patients treated with thrombolysis, the proportional reduction in mortality was the same as for younger patients and the absolute reduction was greater. The elderly perhaps have the most to gain from a treatment that reduces disability from stroke, and thrombolysis certainly deserves a trial at all ages.
A time limit of 6 hours from onset to treatment was set by most of the recent thrombolysis studies, although the sparse data available do not show a sharp increase in adverse effects between 6 and 24 hours. 49 Several Japanese studies have included patients for several days after stroke with no obvious increase in adverse effects. 67 Although it is unlikely that neurons survive many hours of ischemia, we do not really know enough about the duration of neuronal viability after acute cerebral artery occlusion to introduce time limits to treatment. Time limits can only be established by large randomized, controlled trials. In most parts of the world stroke patients go to the hospital (if at all) in a "slow ambulance," and few reach the hospital and have a CT scan by 6 hours. Although it was possible to recruit patients within 90 minutes of symptom onset in the National Institutes of Health (NIH) t-PA study 688 -68 " (and very early recruitment is continuing in the NIH randomized, controlled trial of t-PA), elsewhere in the world it is likely to take many years to change the current slow referral pattern. Therefore, future trials should examine the problem of maximum time limit by including patients up to 24 hours after onset; otherwise, we will never know the risk/benefit ratio of thrombolytic treatment between 6 and 24 hours.
If very early treatment is the aim, is there a danger in exposing patients who are having a transient ischemic attack (TIA) to thrombolysis? Levy 93 found that 50% of TIAs last less than 30 minutes, and in patients with a deficit persisting at 60 minutes, less than 2% will resolve spontaneously in each subsequent 1-hour period. Therefore, there is very little danger in treating a TIA with thrombolysis if patients showing distinct signs of improvement in the first 1-2 hours are excluded.
Which Drug Should Be Used?
Most of the available thrombolytics have been tested in stroke, using oral, intravenous, and intra-arterial routes of administration and a wide range of doses. Table 2 shows that in the small nonrandomized studies thus far there is little difference in immediate patency rates between t-PA, SK, or UK and no obvious optimum dose. The number of patients is small, however, and there may be publication bias. Several open studies have failed to identify an optimum dose. The lack of a clear benefit for one drug or dose is not unexpected. ISIS-3 and GISSI-2 combined had to randomize over 60,000 patients to show that the reduction in vascular deaths after myocardial infarction was the same whether SK, t-PA, or anistreplase was used. But there was a highly significant excess of cerebral hemorrhages with t-PA: seven of 1,000 compared with three of 1,000 with SK. 87 Although studies of thrombolysis in myocardial infarction may not be directly relevant to the use of thrombolysis in acute ischemic stroke, investigators should be aware of the now vast amount of information available from studies of thrombolysis in cardiovascular disease. Extrapolation from ISIS-3 and GISSI-2 suggests that the clinical benefit for thrombolysis in acute ischemic stroke should be about the same no matter which agent is used, but the cerebral hemorrhage rate might be higher after t-PA. Our simple analysis of the available data (Tables 4 and 5 and Figure 2 ) tends to support this, and certainly SK (or any of the other available thrombolytic drugs) should not be rejected in favor of t-PA without being adequately tested.
Conclusions
Experience with thrombolysis in acute ischemic stroke suggests that the risks are not excessive and there may be some benefit. However, the standard of methodology used in most of the trials thus far means that this conclusion must be very tentative and no more than hypothesis generating. It has been enough, however, to encourage Italian, Australian, and American investigators, who have recently started randomized trials of intravenous thrombolysis (SK/aspirin/both or neither, SK/aspirin/placebo, and t-PA/placebo, respectively) in acute ischemic stroke.
Considerable expertise has now accrued showing the value of thrombolysis and aspirin in acute myocardial infarction. As well as demonstrating benefit in young, otherwise healthy, myocardial infarction patients, ISIS-3 has shown that other subgroups of myocardial infarction patients, traditionally regarded as high risk for thrombolysis, gain considerable benefit from it, including the elderly and those with hypertension, previous peptic ulcer, and recent stroke. 87 It is this mass of evidence from the use of thrombolysis in myocardial infarction, as well as the limited experience in ischemic stroke, that makes it imperative and urgent to test thromborysis properly in acute ischemic stroke. There is no place for more nonrandomized trials in this assessment. Safety cannot be assessed unless the major adverse effects of the treatment under trial are controlled for, which in this case mimic the natural history of the disease: cerebral hemorrhage and severe infarct edema.
Acute stroke treatment research is rejecting compounds thought to have therapeutic promise as fast as they can be invented, but with remarkably little good evidence to do so, and this must stop. Thrombolysis in acute myocardial infarction was almost rejected in error after innumerable small trials had missed its real benefit. It was only after the overview of these trials 22 
